Cargando…

The possible of immunotherapy for COVID-19: A systematic review

The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies....

Descripción completa

Detalles Bibliográficos
Autores principales: AminJafari, Akram, Ghasemi, Sorayya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128194/
https://www.ncbi.nlm.nih.gov/pubmed/32272396
http://dx.doi.org/10.1016/j.intimp.2020.106455
_version_ 1783516509765632000
author AminJafari, Akram
Ghasemi, Sorayya
author_facet AminJafari, Akram
Ghasemi, Sorayya
author_sort AminJafari, Akram
collection PubMed
description The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstrated that although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.
format Online
Article
Text
id pubmed-7128194
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71281942020-04-08 The possible of immunotherapy for COVID-19: A systematic review AminJafari, Akram Ghasemi, Sorayya Int Immunopharmacol Article The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstrated that although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option. Elsevier B.V. 2020-06 2020-04-02 /pmc/articles/PMC7128194/ /pubmed/32272396 http://dx.doi.org/10.1016/j.intimp.2020.106455 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
AminJafari, Akram
Ghasemi, Sorayya
The possible of immunotherapy for COVID-19: A systematic review
title The possible of immunotherapy for COVID-19: A systematic review
title_full The possible of immunotherapy for COVID-19: A systematic review
title_fullStr The possible of immunotherapy for COVID-19: A systematic review
title_full_unstemmed The possible of immunotherapy for COVID-19: A systematic review
title_short The possible of immunotherapy for COVID-19: A systematic review
title_sort possible of immunotherapy for covid-19: a systematic review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128194/
https://www.ncbi.nlm.nih.gov/pubmed/32272396
http://dx.doi.org/10.1016/j.intimp.2020.106455
work_keys_str_mv AT aminjafariakram thepossibleofimmunotherapyforcovid19asystematicreview
AT ghasemisorayya thepossibleofimmunotherapyforcovid19asystematicreview
AT aminjafariakram possibleofimmunotherapyforcovid19asystematicreview
AT ghasemisorayya possibleofimmunotherapyforcovid19asystematicreview